Log in

Where are They Now?

Past Fellowship Recipients

Dr. Tina Hsu

2012 Recipient

PHYSICAL, EMOTIONAL AND SOCIAL STRESSORS AND THEIR IMPACT ON QUALITY OF LIFE OF CAREGIVERS OF ELDERLY PATIENTS WITH CANCER


What was your CAMO Fellowship project?

My Fellowship project was on characterizing caregivers of older adults with cancer admitted to hospital and understanding potential physical, social and psychological stressors affecting them. 

Where did you do (location) your CAMO Fellowship?

I did my Fellowship at City of Hope Comprehensive Cancer Centre in Duarte California USA under the mentorship of Dr. Arti Hurria.

How do you think the CAMO Fellowship influenced your career?

This Fellowship was critical in helping me develop the research skills, as well as contacts within the field of geriatric oncology, that I continue to cultivate today. It has lead to a variety of research collaborations, but also invitations to be a part of international committees and panels and undoubtedly played a large part in being invited to speak at international conferences. 

Where are you now?

I am staff physician medical oncologist in Ottawa. 

Publications from CAMO Fellowship

Tina Hsu, MD1; Matthew Loscalzo, LCSW2; Rupal Ramani, BS1; Stephen Forman, MD3; Leslie Popplewell, MD3; Karen Clark, MS4; Vani Katheria, MS1; Tao Feng, MS1; Rex Strowbridge, AA5,6; Redmond Rinehart, BS5; Dan Smith5; Keith Matthews, AS5; Jeff Dillehunt, AS5; and Arti Hurria, MD1 “Factors Associated With High Burden in Caregivers of Older Adults With Cancer” Cancer 2014;120:2927-35. VC 2014.

Dr. Vincent Tam

2010 Recipient

A PHASE II TRIAL COMPARING LOW DOSE METRONOMIC CYCLOPHOSPHAMIDE AND CEDIRANIB TO CYCLOPHOSPHAMIDE AND PLACEBO AS MAINTENANCE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER


What was your CAMO Fellowship project?

My initial project was a phase II trial of an angiogenesis inhibitor in the treatment of metastatic colon cancer, but unfortunately the study did not end up being funded, although I did learn a great deal regarding the design of phase II clinical trials. I subsequently completed and published a cost-effectiveness analysis dealing with treatments for metastatic pancreatic cancer and a national study examining oncology education in undergraduate and postgraduate family medicine and internal medicine programs in Canada. 

Where did you do (location) your CAMO Fellowship?

Sunnybrook Odette Cancer Centre, Toronto

How do you think the CAMO Fellowship influenced your career?

My Fellowship training was in GI Medical Oncology, phase II trials and oncology education. I have put this training to good use and am currently treating GI cancers, extensively involved in undergraduate medical education (teaching and curriculum design) and am the local principal investigator for a number of phase II and III hepatobiliary cancer trials. 

Where are you now?

I am a staff medical oncologist at the Tom Baker Cancer Centre / University of Calgary

Publications from CAMO Fellowship

  1. Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KK. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013 Apr;20(2):e90-e106.
  2. Tam VC, Berry S, Hsu T, North S, Neville A, Chan K, Verma S. Oncology education in Canadian undergraduate and postgraduate medical programs: a survey of educators and learners. Curr Oncol. 2014 Feb;21(1):e75-88.
  3. Lien K, Tam VC, Ko YJ, Mittmann N, Cheung MC, Chan KK. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer. Curr Oncol. 2015 Dec;22(6):e443-52.

Dr. Janine Davies

2008 Recipient

PHASE IB STUDY OF SORAFENIB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA AND CHILD’S B CIRRHOSIS


What was your CAMO Fellowship project?

My Fellowship project was a Phase IB Clinical Trial of Sorafenib in Combination with Transarterial Chemoembolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma.

Where did you do (location) your CAMO Fellowship?

I did my Fellowship at the University of North Carolina at Chapel Hill. 

How do you think the CAMO Fellowship influenced your career?

My Fellowship was immensely important in my career. It provided me with specific research training and mentorship that wouldn’t have been possible as a junior staff oncologist. The clinical focus in GI and phase I clinical trials also allowed me to gain unique expertise.

Where are you now?

I initially worked at the BC Cancer Agency Centre for the Southern Interior in Kelowna, and have recently relocated to the BC Cancer Agency Vancouver Centre.

Dr. Philippe Bedard

2008 Recipient

DETERMINANTS OF GENOMIC RISK IN EARLY-STAGE BREAST CANCER


What was your CAMO Fellowship project?

Determinants of genomic risk in early-stage breast cancer

Where did you do (location) your CAMO Fellowship?

Institut Jules Bordet, Breast International Group, Brussels, Belgium

How do you think the CAMO Fellowship influenced your career?

Through my CAMO fellowship, I gained experience in oncology clinical research, developed a network of worldwide contacts in breast cancer medicine, and catalyzed an interest in early stage drug development and clinical genomics that has shaped my early career development.

Where are you now?

Staff Medical Oncologist, Princess Margaret Cancer Centre, Associate Professor of Medicine, University of Toronto

Publications from CAMO Fellowship

  1. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clinical Cancer Research. 2012 Mar 1;18(5):1341-51. Impact Factor 7.742. Coauthor or Collaborator.
  2. Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart MJ, Sotiriou C. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. Endocrine Related Cancer. 2011 Dec 1;18(6):721-30. Impact Factor 4.364. Principal Author.
  3. Bedard PL, Cardoso F. Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? Nature Reviews Clinical Oncology. 2011 May 1;8(5):272-9. Review. Impact Factor 11.963. Principal Author.
  4. Bedard PL, Bernard-Marty C, Raimondi C and Cardoso F. The role of capecitabine in the management of breast cancer in elderly patients. Journal of Geriatric Oncology. 2011;2(1):72-81. Impact Factor 1.18. Principal Author. 
  5. Toussaint J, Durbecq V, Altintas S, Doriath v, Rouas G, Paesmans M, Bedard B, Haibe-Kains B, Tjalma WA, Larsimont D, Piccart M, Sotiriou C. Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS). PLoS ONE. 5:pii:e12100, August 2010. Impact Factor 4.411. Coauthor or Collaborator.
  6. Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, van ‘t Veer LJ. Identification of a low-risk subgroup of HER-2- positive breast cancer by the 70-gene prognosis signature. British Journal of Cancer. 2010;103(12):1788-93. 2010 Nov 16. [Epub ahead of print]. Impact Factor 5.042. Coauthor or Collaborator. 
  7. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nature Reviews Clinical Oncology. 2010;7(1):22-36. Review. Impact Factor 11.963. Principal Author. 8 WHERE ARE THEY NOW (past CAMO fellows)… Dr. Philippe Bedard
  8. Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Critical Reviews Oncology & Hematology. 2010;75(2):110-21. [Epub ahead of print]. Impact Factor 4.411. Coauthor or Collaborator.
  9. Bedard PL, Piccart-Gebhart MJ. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. Curr Opin Oncol. 2009 Nov 1;21(6):491-8. Review. Impact Factor 4.1. Principal Author.
  10. Bedard PL, Body J-J, and Piccart-Gebhart MJ. Sowing the Soil for Cure? The Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer. J Clin Oncol. 2009 Aug 3;27:4043-4046. Editorial. Impact Factor 18.372. Principal Author.
  11. Bedard PL, Mook S, Piccart-Gebhart MJ, Rutgers ET, Van’t Veer LJ, Cardoso F. MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. Expert Opin Med Diagn. 2009 Mar 1;3(2):193-205. Principal Author.
  12. Snoj N, Bedard PL, de Azambuja E, Cardoso F, and Piccart M. Are we HER-ting for innovation in neoadjuvant clinical trial design? Br Cancer Res. 2009 Jan 16;11(1):201. Impact Factor 5.245. Coauthor or Collaborator.
  13. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS, ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17):1174-81. [Epub ahead of print] August 5, 2009. Impact Factor 13.757. Co-Principal Author. 
  14. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol. 2009;4(2):77-88. Review. Impact Factor 2.76. Coauthor or Collaborator.
  15. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 2009;14(1):55-66. Review. Impact Factor 7.524. Principal Author. 
  16. Bedard PL, Dinh P, Sotiriou C, and Piccart-Gebhart MJ. Aiming at the target: improved adjuvant medical therapy. Breast. 2009;Supp 3:S25-30. Impact Factor 1.97. Principal Author.
  17. Snoj N, Bedard PL, de Azambuja E, Cardoso F, Piccart M. Are we HER-ting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res. 2009;11(1):201. Coauthor or Collaborator.
  18. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets. 2009;9(2):148-62. Review. Impact Factor 4.33. Principal Author. 
  19. Bedard PL, Cardoso F. Recent advances in adjuvant systemic therapy for early-stage breast cancer. Ann Oncol. 2008 Jul 1;19 Suppl 5:v122-7. Review. Impact Factor 6.425. Principal Author.
  20. Bedard PL, Piccart-Gebhart MJ. Nonhormonal systemic therapy for advanced breast cancer: do the math! J Natl Cancer Inst. 2008;100(24):1745-7. Editorial. Impact Factor 13.757. Principal Author.
  21. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted 

Dr. Daniel Heng

2007 Recipient

A PHASE II STUDY OF SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCC) REFRACTORY TO PRIOR SUNITINIB OR BEVACIZUMAB THERAPY.


What was your CAMO Fellowship project?

It was a phase II trial of sorafenib in kidney cancer. Interestingly, this trial never finished because the question was answered somewhere else later on in my Fellowship (ie we were scooped). However, it did allow me to embark on several other projects that have become very productive. 

Where did you do (location) your CAMO Fellowship?

Cleveland Clinic Taussig Cancer Institute

How do you think the CAMO Fellowship influenced your career?

The CAMO Fellowship was extremely important to me as I was able to meet and network with world famous people and build bridges for research in Canada. There are so many opportunities in the US ripe for the picking by a Canadian Fellow that can be brought back to Canada. Without the CAMO Fellowship I would have not had the chance to go to Cleveland and meet my current mentors. I would not have been able to build/chair the International mRCC Database Consortium without this Fellowship. 

Where are you now?

GU Tumor Group Chair, Tom Baker Cancer Center and University of Calgary, Calgary, Alberta

Dr. Christine Simmons

2006 Recipient

CHANGES IN BREAST TUMOR RECEPTOR STATUS WITH TIME-DOES PERFORMING A CONFIRMATORY BIOPSY AT THE TIME OF METASTIC RECURRENCE ALTER PATIENT MANAGEMENT?


What was your CAMO Fellowship project?

My Fellowship project was (I believe) the first prospective study to assess change in tumour receptor status at the time of metastatic recurrence of breast cancer. We prospectively biopsied patients presenting with radiographic evidence of recurrence to determine if receptor status (ER/PR/Her2) changed with time. Previous studies in this area had relied on retrospective tumour banks which could have been subject to selection bias. This study received peer reviewed grant funding from CBCF as well, and I was given the opportunity to write and construct the grant application for this process. Publication from this project is below. Also was presented at ASCO and received an ASCO Merit award. Simmons CE, Miller N, Geddie W, Gianfelice D, Oldfield M, DranitsarisG, Clemons MJ. “Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?”. Ann Oncol. 2009 Sep:20(9):1499-504. Epub 2009 Mar 18. PubMed PMID: 19299408; PubMed Central PMCID: PMC2731014. 

Where did you do (location) your CAMO Fellowship?

Princess Margaret Hospital in Toronto 

How do you think the CAMO Fellowship influenced your career?

Absolutely. My Fellowship gave me the opportunity to learn about the most effective ways of conducting research, gave me the opportunity to receive excellent mentorship from a variety of sources, and helped me to solidify my interests in research and teaching. 

Where are you now?

I am staff physician medical oncologist at the BC Cancer Agency in Vancouver. I sub-specialize in breast cancer and sarcoma. I also am the Course Director for clinical skills in the undergraduate medical program at UBC, and founder and chair of a not-for-profit organization (Women in Cancer/All in Cancer) which focuses in improving mentorship connections across the country. So in these ways, I am truly “paying it forward” – the investment CAMO made in me I am continuously grateful for! 

Publications from CAMO Fellowship

  1. Broom R, Simmons CE, Clemons M, Cole DEC, Dranitsaris G. “The role of urinary N-telopeptides in evaluating the palliative benefit of bisphosphonates in metastatic breast cancer”. Progress in Palliative Care. Feb 2007. 15(1):1-5.
  2. Broom RJ, Simmons CE, Clemons M. “Oral bisphosphonates as adjuvant therapy for operable breast cancer”. Hospital Pharmacy Europe May/June 2007 issue p 41-43.
  3. Clemons M, Simmons CE. “Identifying menopause in breast cancer patients: considerations and implications”. Breast Cancer Research and Treatment. 2007 Aug;104(2):115-20. Epub 2006 Oct 24. Review PubMed PMID: 17061039.
  4. Petrut B, Trinkaus M, Simmons CE, Clemons M. “A primer of bone metastases management in breast cancer patients”. Curr Oncol. 2008 Jan;15 (Supplement 1):S50-7.
  5. Trinkaus M, Chin S, Wolfman W, Simmons CE, Clemons M. “Should urogenital atrophy in breast cancer survivors be treated with topical estrogens”? Oncologist 2008 Mar;13(3):222-31. Review. PubMed PMID 18378532.

  6. Petrut B, Simmons CE, Broom R, Trinkaus M, Clemons M. “Pharmacotherapy of bone metastases in breast cancer patients”. Expert Opin Pharmacother. 2008 Apr;9(6):937-45. Review. PubMed PMID: 18377337. 

  7. Simmons CE, Broom RJ, Cole DE, Dranitsaris G, Clemons M. “Urinary N-telopeptide is a Rapid Predictor of Response and Palliative Benefit from Bisphosphonate Therapy in Metastatic Breast Cancer Patients”. Supportive Cancer Therapy, 2008 Sep 1;4(4):182-7. PubMed PMID: 18632515.

  8. Amir E, Ooi W, Simmons CE, Khan H, Christaskis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. “Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies.”. Clinical Oncology, (R Coll Radio). 2008, Dec; 20 (10): 763-8.Epub 2008 Sept 27. PubMed PMID 18824337.

  9. Chin S, Trinkaus M, Simmons CE, Bolivar R, Flynn C, Clemons M. “Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer”. Clinical Breast Cancer 2009 May; 9(2): 108-17. PubMed PMID: 19433392.

  10. Broom RJ, Tang PA, Simmons CE, Bordeleau L, Mulligan AM, O’Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ. “Changes in estrogen receptor, progesterone receptor, and Her2/neu status with time: discordance rates between primary and metastatic breast cancer.”. Anticancer Res. 2009 May: 29(5):1557-62. PubMed PMID: 19443366.

  11. Amir E, Trinkaus M, Simmons CE, Dranitsaris G, Clemons MJ. “Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.”. Journal of Clinical Pathology. 2009 May; 62(5):474-6. PubMed PMID: 19398598.

  12. Simmons CE, Amir E, Dranitsaris G, Clemons M, Wong B, Veith R, Cole DE. “Altered calcium metabolism in patient on long-term bisphosphonate therapy for metastatic breast cancer”. Anticancer Research 2009 Jul;29(7):2707-11. PubMed PMID: 19596950.

  13. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons CE, Ooi W, Cella D. “Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of cancer Therapy-Bone Pain”. J Pain Symptom Manage, 2009 Aug:38(2):244-57.

  14. Simmons CE, Miller N, Geddie W, Gianfelice D, Oldfield M, DranitsarisG, Clemons MJ. “Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?”. Ann Oncol. 2009 Sep:20(9):1499-504. Epub 2009 Mar 18. PubMed PMID: 19299408; PubMed Central PMCID: PMC2731014.

  15. Amir E, Simmons CE, (co-primary author), Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. “ A phase II trial exploring the effects of high-dose (10,000IU/day) vitamin D(3( in breast cancer patients with bone metastases. Cancer 2010 15;116(2):284-91. PubMed PMID: 19918922.

  16. Trinkaus M, Simmons CE, Myers J, Dranatisaris G, Clemons M. “Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the non-trial setting”. Support Care Cancer: 2010 Feb:18(2):197-203. Epub 2009 May 8. PubMed PMID: 19424729.


Canadian Association of Medical Oncologists
1309 Carling Ave
PO Box 35164 Westgate
Ottawa, ON K1Z 1A2

Phone: 613.415.6033
Fax: 866.839.7501
Email: info@camo-acom.ca

Powered by Wild Apricot Membership Software